Epicardial Ablation in Brugada Syndrome
Epicardial Ablation in Brugada Syndrome
This prospective study evaluates the methodology and results of epicardial mapping/ablation
 in a large series of consecutive selected BrS patients and to verify if RFA could normalize
 the consequences of a genetic disease.
The present Registry is designed as a prospective, monocentric study. All patients referred
 to the Arrhythmology Department of IRCCS Policlinico San Donato Milanese, University-
 Hospital, for the management of BrS and fulfilling the selection criteria will be invited to
 participate in the study and will be asked their written consent to the participation in the
 trial.

 Mapping and RFA procedure will be performed following a standardized procedure in hospital
 settings. Patients will be monitored for at least 3 days after procedure.

 Before hospital discharge, echocardiography and 12-lead ECG will be performed in all
 patients. An ajmaline test will be systematically performed after the procedure and
 thereafter at 3, 6, and 12 months after ablation.

 Patients will be followed up clinically after procedure as per normal clinical practice.
 Follow-up visits will be scheduled at 3, 6, and 12 months. 12-lead ECG and ICD interrogation
 will be performed at each follow-up visits. Patients will be instructed to immediately
 contact the center in case of symptoms suggestive of ventricular arrhythmias. Documentation
 for intercurrent events will be requested and collected.
Inclusion Criteria:

 -  Patients affected by Brugada Syndrome, profiled by genetic testing, with documented
 spontaneous or drug-induced type I BrS ECG pattern, with symptoms attributable to
 ventricular arrhythmias and presenting multiple documented arrhythmic episodes

 -  Patients with an ICD already implanted

 -  Patients referred to the center for an electrophysiological study and indication to a
 potential concomitant radio-frequency catheter ablation (RFA) of ventricular
 arrhythmia or ventricular fibrillation

 -  Age ≥ 18

 -  Willingness to attend follow-up examinations

 -  Written informed consent to the participation in the trial

 Exclusion Criteria:

 -  Pregnancy or breast-feeding

 -  Patients with low arrhythmic risk (Brugada pattern III)

 -  Life expectancy < 12 months.